NPS Intelligence (beta)

Disclosed NPS & retention by vertical

Verticals  /  Pharma, medtech & health distribution  /  Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc.

sorrentotherapeutics.com ↗
—
Latest disclosed NPS
no score published
4
NPS entries
0 with a number
2018–22
Years covered
4 entries in all

In their words

“Economic value; comparisons with various stock market indices; stockholders’ equity; market recognition (including but not limited to awards and analyst ratings); financial ratios; net promoter score; customer satisfaction; and strategic team goals.”
— Sorrento Therapeutics, Inc. · SEC 8-K filing · filed 16 Dec 2022
“Economic value; comparisons with various stock market indices; stockholders’ equity; market recognition (including but not limited to awards and analyst ratings); financial ratios; net promoter score; customer satisfaction; and strategic team goals.”
— Sorrento Therapeutics, Inc. · SEC 8-K filing · filed 20 Oct 2020
“Economic value; comparisons with various stock market indices; stockholders’ equity; market recognition (including but not limited to awards and analyst ratings); financial ratios; net promoter score; customer satisfaction; and strategic team goals.”
— Sorrento Therapeutics, Inc. · SEC proxy statement · filed 14 Aug 2019

NPS disclosures (4)

Search the database →

16 Dec 2022
NPSProgram

…economic value; comparisons with various stock market indices; stockholders’ equity; market recognition (including but not limited to awards and analyst ratings); financial ratios; net promoter score; customer satisfaction; and strategic team goals.

— Sorrento Therapeutics, Inc. · SEC 8-K filing · filed 16 Dec 2022
SEC 8-K filing ↗
20 Oct 2020
NPSProgram

…economic value; comparisons with various stock market indices; stockholders’ equity; market recognition (including but not limited to awards and analyst ratings); financial ratios; net promoter score; customer satisfaction; and strategic team goals.

— Sorrento Therapeutics, Inc. · SEC 8-K filing · filed 20 Oct 2020
SEC 8-K filing ↗
14 Aug 2019
NPSProgram

…economic value; comparisons with various stock market indices; stockholders’ equity; market recognition (including but not limited to awards and analyst ratings); financial ratios; net promoter score; customer satisfaction; and strategic team goals.

— Sorrento Therapeutics, Inc. · SEC proxy statement · filed 14 Aug 2019
SEC proxy statement ↗
28 Aug 2018
NPSProgram

…economic value; comparisons with various stock market indices; stockholders’ equity; market recognition (including but not limited to awards and analyst ratings); financial ratios; net promoter score; customer satisfaction; and strategic team goals.

— Sorrento Therapeutics, Inc. · SEC 8-K filing · filed 28 Aug 2018
SEC 8-K filing ↗

Retention disclosures (0)

Open in the retention database →

No retention figures yet.

Lighthouse companies in Pharma, medtech & health distribution

The whole vertical →

About these figures

Every figure here was publicly disclosed by the named company: press releases, annual reports, SEC filings, earnings calls and news coverage. Companies tend to publish their NPS when it is good, so these numbers run higher than a true industry average: read them as what leading companies in this vertical say publicly, not as an industry benchmark.

NPS runs from −100 to +100. Retention figures are reported as the company defines them (net revenue retention, gross revenue retention, customer retention rate, churn). Every entry links to its source in the full database.